ArticleJapanese journal of ophthalmology2026
Involvement of ocular angle pigmentation on the effect of 2% topical ganciclovir treatment in patients with cytomegalovirus anterior uveitis.
Article in Japanese journal of ophthalmology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
Abstract
purposeTopical ganciclovir (GCV) reduces intraocular pressure (IOP) in patients with cytomegalovirus (CMV) anterior uveitis. Because increased angle pigmentation may contribute to aqueous outflow resistance, we investigated the relationship between angle pigmentation and the IOP-lowering effects of topical GCV. STUDY
designRetrospective study.
methodsWe reviewed the medical records of 31 eyes of 31 patients diagnosed with CMV anterior uveitis using aqueous humor PCR and treated with 2% topical GCV at the University of Tokyo Hospital. The best-corrected visual acuity (BCVA), IOP, topical steroids, and glaucoma medication scores were evaluated at baseline, 1, 4, 12, and 24 weeks after GCV initiation. Pre-treatment angle pigmentation was graded and analyzed in relation to IOP. Survival analysis was performed, with failure defined as an IOP > 21 mmHg, or the need for glaucoma surgery.
resultsTopical GCV improved BCVA with gradual reductions in IOP, steroid use, and glaucoma medication. Angle pigmentation was lower in CMV-affected eyes than in fellow eyes in patients with a shorter disease duration. Higher angle pigmentation was significantly correlated with a longer disease duration (ρ = 0.51, p = 0.003). The greater-pigmentation group showed significantly less IOP reduction and lower survival rates than the less-pigmentation group.
conclusionAngle pigmentation was lower in the affected eyes than in the fellow eyes in patients with a shorter disease duration. In contrast, patients with greater angle pigmentation exhibited longer disease duration and a reduced IOP-lowering response to topical GCV treatment. Therefore, pre-treatment angle pigmentation evaluation may assist in predicting glaucoma outcomes.
Indexed as
Identifiers
42911522What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.